|Bid||73.70 x 300|
|Ask||74.33 x 800|
|Day's range||73.18 - 74.42|
|52-week range||63.76 - 89.54|
|PE ratio (TTM)||21.00|
|Earnings date||1 May 2018|
|Forward dividend & yield||2.28 (3.03%)|
|1y target est||88.95|
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.
Antipodes is also quite contrarian. Antipodes is located Down Under, but its performance has been Up Above. The Antipodes Global Fund-Long Only, the Antipodes Global fund, and the Antipodes Asia fund all adopted new strategies on June 30, 2015, and since then, through the first quarter of 2018, they are up 44.9%, 42.4%, and 34.4%, respectively, in absolute performance.
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
Gilead Sciences, Inc. announced today that its first quarter 2018 financial results will be released on Tuesday, May 1, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2018 and provide a general business update.
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.
Investing success can sometimes be achieved by looking beyond the obvious choices. Check out the growth potential of Shopify, Atara Bio, and Criteo.
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
More than 25 additional Gilead abstracts on NASH and other fibrotic liver diseases are also being presented, including data from predictive modeling studies using noninvasive tests for the diagnosis and monitoring of NASH that aim to reduce the need for liver biopsy.
Gilead Sciences, Inc. today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis , combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor agonist GS-9674.
Big biotech stocks are trading at their lowest valuations in years, but don’t underestimate their ability to turn things around quickly.
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
Mark Keller, chief executive and chief investment officer of Confluence Investment Management, focuses on conglomerates, so it’s not surprising that the advisor had held a large position in General Electric. What’s surprising is that Confluence, which is based in St. Louis, sold in the first quarter all 2.8 million GE (GE) shares that it had held at the end of 2017, according to regulatory filings. Elsewhere, Keller and Confluence, which managed $5.4 billion in U.S.-traded securities at the end of the first quarter, was in a mood for buying well-known names in the period.